Evidence map›Paper›PMID 35455990›Full record

ArticleCells2022

Simon J L Petitjean, Marylène Lecocq, Camille Lelong, Robin Denis, Sylvie Defrère, Pierre-Antoine Mariage, David Alsteens, Charles Pilette

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Apoptotic body-encapsulated zinc-dopedMaterials today. Bio · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Recent developments inFrontiers in pharmacology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Simon J L PetitjeanLouvain Institute of Biomolecular Science and Technology, Université Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium.
Marylène LecocqPole of Pneumology, ENT and Dermatology, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, 1348 Brussels, Belgium.
Camille LelongBOTALYS, 8 Avenue des Artisans, 7822 Ghislenghien, Belgium.
Robin DenisBOTALYS, 8 Avenue des Artisans, 7822 Ghislenghien, Belgium.
Sylvie DefrèreBOTALYS, 8 Avenue des Artisans, 7822 Ghislenghien, Belgium.
Pierre-Antoine MariageBOTALYS, 8 Avenue des Artisans, 7822 Ghislenghien, Belgium.
David AlsteensLouvain Institute of Biomolecular Science and Technology, Université Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium.ORCID 0000-0001-9229-113X
Charles PilettePole of Pneumology, ENT and Dermatology, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, 1348 Brussels, Belgium.
UCLouvain · BECliniques Universitaires Saint-Luc · BEWalloon Excellence in Lifesciences and Biotechnology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentSalvia miltiorrhizaAngiotensin-Converting Enzyme 2Medicine, Chinese TraditionalNF-kappa BSARS-CoV-2Angiotensin-Converting Enzyme 2NF-kappa BACE2AFMatomic force microscopybinding inhibitorCOVID-19force spectroscopyinfectionSARS-CoV-2single-moleculeviral entry

Identifiers

PMID35455990
PMCPMC9028742
OpenAlexW4223511627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.